Elvina Almuradova: Promising results from the NO-CUT trial in pMMR LARC patients

Elvina Almuradova, Associate Professor, Medicana Health Group, shared a post on LinkedIn:

“Promising results from the NO-CUT trial (TNT with a nonoperative approach) in pMMR LARC patients:

• Distant Relapse-Free Survival (DRFS30)**: 96.9% in the NOM cohort vs. 74% in the ReSU cohort
• Local regrowth**: 15% in NOM vs. 9% in ReSU
• Deaths**: 12 deaths (6.6%), including 1 AE-related and 9 tumor-related
• Circulating tumor DNA**: Correlated with cCR and DRFS in the first 77 patients.”

Source: Elvina Almuradova/LinkedIn